Hepatic Stellate Cell Phenotypes in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Author Contributions

Both authors contributed equally to Conceptualization, Methodology, Data Curation, Writing, Review & Editing of this manuscript.

Ethics Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The statement is required for all original articles which informs readers about the accessibility of research data linked to a paper and outlines the terms under which the data can be obtained.

Funding

This research received no external funding.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Kisseleva T, Ganguly S, Murad R, Wang A, Brenner DA. Regulation of hepatic stellate cell phenotypes in MASH. Gastroenterology 2025, in press. doi:10.1053/j.gastro.2025.03.010.

[2] Steinberg GR, Valvano CM, De Nardo W, Watt MJ. Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms. J. Hepatol. 2025, in press. doi:10.1016/j.jhep.2025.02.033.

[3] Younossi ZM, Razavi H, Sherman M, Allen AM, Anstee QM, Cusi K, et al. Addressing the high and rising global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): From the growing prevalence to Payors’ perspective. Aliment Pharmacol. Ther. 2025, in press. doi:10.1111/apt.70020.

[4] Acharya P, Chouhan K, Weiskirchen S, Weiskirchen R. Cellular mechanisms of liver fibrosis. Front. Pharmacol. 2021, 12, 671640. doi:10.3389/fphar.2021.671640.

[5] Kim HY, Rosenthal SB, Liu X, Miciano C, Hou X, Miller M, et al. Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease. J. Hepatol. 2024, in press. doi:10.1016/j.jhep.2024.10.044.

[6] Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory from the American Heart Association. Circulation 2023, 148, 1606-1635. doi:10.1161/CIR.0000000000001184; Erratum in Circulation 2024, 149, e1023. doi:10.1161/CIR.0000000000001241.

[7] Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J. Cell. Mol. Med. 2006, 10, 76-99. doi:10.1111/j.1582-4934.2006.tb00292.x.

[8] Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin. Liver Dis. 2021, 41, 421-434. doi:10.1055/s-0041-1730927.

[9] Zheng D, Jiang Y, Qu C, Yuan H, Hu K, He L, et al. Pyruvate kinase M2 tetramerization protects against hepatic stellate cell activation and liver fibrosis. Am. J. Pathol. 2020, 190, 2267-2281. doi:10.1016/j.ajpath.2020.08.002.

[10] Luo W, Hu H, Chang R, Zhong J, Knabel M, O’Meally R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011, 145, 732-744. doi:10.1016/j.cell.2011.03.054.

[11] Liu Y, Zheng Y, Yang Y, Liu K, Wu J, Gao P, et al. Exosomes in liver fibrosis: The role of modulating hepatic stellate cells and immune cells, and prospects for clinical applications. Front. Immunol. 2023, 14, 1133297. doi:10.3389/fimmu.2023.1133297.

[12] Yu W, Wang S, Wang Y, Chen H, Nie H, Liu L, et al. MicroRNA: role in macrophage polarization and the pathogenesis of the liver fibrosis. Front. Immunol. 2023, 14, 1147710. doi:10.3389/fimmu.2023.1147710.

[13] Guo Q, Furuta K, Islam S, Caporarello N, Kostallari E, Dielis K, et al. Liver sinusoidal endothelial cell expressed vascular cell adhesion molecule 1 promotes liver fibrosis. Front. Immunol. 2022, 13, 983255. doi:10.3389/fimmu.2022.983255.

[14] Jamalinia M, Lonardo A, Weiskirchen R. Sex and gender differences in liver fibrosis: Pathomechanisms and clinical outcomes. Fibrosis 2024, 2, 10006. doi:10.70322/fibrosis.2024.10006.

[15] Smiriglia A, Lorito N, Bacci M, Subbiani A, Bonechi F, Comito G, et al. Estrogen-dependent activation of TRX2 reverses oxidative stress and metabolic dysfunction associated with steatotic disease. Cell Death Dis. 2025, 16, 57. doi:10.1038/s41419-025-07331-7.

[16] Lonardo A, Ballestri S, Baffy G, Weiskirchen R. Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease. Metab. Target Organ Damage 2024, 4, 41. doi:10.20517/mtod.2024.42.

[17] Tilg H, Byrne CD, Targher G. NASH drug treatment development: challenges and lessons. Lancet. Gastroenterol. Hepatol. 2023, 8, 943-954. doi:10.1016/S2468-1253(23)00159-0.

[18] Lonardo A, Ballestri S, Mantovani A, Targher G, Bril F. Endpoints in NASH clinical trials: Are we blind in one eye? Metabolites 2024, 14, 40. doi:10.3390/metabo14010040.

[19] Lonardo A. Liver fibrosis: More than meets the eye. Ann. Hepatol. 2024, 29, 101479. doi:10.1016/j.aohep.2024.101479.

[20] Olbrich H, Fliegauf M, Hoefele J, Kispert A, Otto E, Volz A, et al. Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis. Nat. Genet. 2003, 34, 455-459. doi:10.1038/ng1216.

[21] Vieira Barbosa J, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal N, et al. Fibrosis-4 index can independently predict major adverse cardiovascular events in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 2022, 117, 453-461. doi:10.14309/ajg.0000000000001606.

[22] Stefan N, Lonardo A, Targher G. Role of steatotic liver disease in prediction and prevention of cardiometabolic diseases. Nat. Rev. Gastroenterol. Hepatol. 2024, 21, 136-137. doi:10.1038/s41575-023-00880-2.

[23] Jamalinia M, Lonardo A, Weiskirchen R. Abdominal aortic aneurysm and liver fibrosis. Clinical evidence and molecular pathomechanics. Preprints 2025, doi:10.20944/preprints202503.0790.v1.

[24] Garbuzenko DV. Mechanisms of epigenetic regulation in the fibrogenic activation of hepatic stellate cells in non-alcoholic fatty liver disease. Gene Exp. 2024, 23, 31-43. doi:10.14218/GE.2023.00090.

[25] Tarantino G, Citro V, Capone D. Nonalcoholic fatty liver disease: A challenge from mechanisms to therapy. J. Clin. Med. 2019, 9, 15. doi:10.3390/jcm9010015.